Profit Investment Management Has Decreased Insteel Industries (IIIN) Stake, Rigel Pharmaceuticals (RIGL) Sentiment Is 0.74

June 20, 2017 - By Adrian Mccoy

Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The company has market cap of $324.78 million. The Firm is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. It currently has negative earnings. The Company’s pioneering research focuses on signaling pathways that are critical to disease mechanisms.

Profit Investment Management Llc decreased Insteel Industries Inc (IIIN) stake by 14.99% reported in 2016Q4 SEC filing. Profit Investment Management Llc sold 10,716 shares as Insteel Industries Inc (IIIN)’s stock declined 14.26%. The Profit Investment Management Llc holds 60,763 shares with $2.17 million value, down from 71,479 last quarter. Insteel Industries Inc now has $607.67 million valuation. The stock increased 0.22% or $0.07 during the last trading session, reaching $31.91. About shares traded. Insteel Industries Inc (NASDAQ:IIIN) has risen 28.48% since June 20, 2016 and is uptrending. It has outperformed by 11.78% the S&P500.

Since February 12, 2017, it had 0 buys, and 6 selling transactions for $1.86 million activity. Wagner Richard sold $654,624 worth of Insteel Industries Inc (NASDAQ:IIIN) on Monday, May 22. Jafroodi Scot R also sold $195,899 worth of Insteel Industries Inc (NASDAQ:IIIN) shares. On Sunday, February 12 PETELLE JAMES F sold $99,580 worth of Insteel Industries Inc (NASDAQ:IIIN) or 2,642 shares.

Analysts await Insteel Industries Inc (NASDAQ:IIIN) to report earnings on July, 20.

Investors sentiment decreased to 1.02 in 2016 Q4. Its down 0.40, from 1.42 in 2016Q3. It worsened, as 36 investors sold IIIN shares while 47 reduced holdings. 36 funds opened positions while 49 raised stakes. 15.79 million shares or 10.60% more from 14.28 million shares in 2016Q3 were reported. Cortina Asset Mgmt Ltd Liability stated it has 0.23% of its portfolio in Insteel Industries Inc (NASDAQ:IIIN). Credit Suisse Ag has invested 0% in Insteel Industries Inc (NASDAQ:IIIN). American Century accumulated 0% or 88,814 shares. Tower Research Cap Ltd Liability Co (Trc), a New York-based fund reported 98 shares. The New York-based Cornerstone Cap Mngmt Hldg Ltd Liability has invested 0% in Insteel Industries Inc (NASDAQ:IIIN). Cadence Ltd has 31,763 shares for 0.08% of their portfolio. Pacific Invest holds 0.72% or 99,020 shares. State Of Tennessee Treasury Department holds 14,120 shares. Vanguard Gru holds 0% or 1.22 million shares. Susquehanna Group Ltd Liability Partnership invested 0% in Insteel Industries Inc (NASDAQ:IIIN). Ahl Prtnrs Ltd Liability Partnership reported 0.01% stake. Tudor Corporation Et Al reported 14,500 shares or 0.01% of all its holdings. Pacad Invest Limited, British Columbia – Canada-based fund reported 4,300 shares. Invesco Ltd holds 239,354 shares or 0% of its portfolio. Michigan-based Comerica National Bank & Trust has invested 0.01% in Insteel Industries Inc (NASDAQ:IIIN).

Among 3 analysts covering InSteel Industries (NASDAQ:IIIN), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. InSteel Industries had 3 analyst reports since July 22, 2016 according to SRatingsIntel. Rosenblatt maintained the stock with “Neutral” rating in Friday, July 22 report. As per Tuesday, November 22, the company rating was upgraded by Sidoti.

The stock increased 11.20% or $0.28 during the last trading session, reaching $2.78. About shares traded. Rigel Pharmaceuticals, Inc. (RIGL) has risen 4.56% since June 20, 2016 and is uptrending. It has underperformed by 12.14% the S&P500.

Since January 1, 0001, it had 0 insider buys, and 1 sale for $12,028 activity.

Analysts await Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) to report earnings on August, 1. They expect $-0.14 earnings per share, up 6.67% or $0.01 from last year’s $-0.15 per share. After $-0.13 actual earnings per share reported by Rigel Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 7.69% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: